CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ANTICARB develops a novel cancer treatment by combining carbon nanotubes with targeted antibody therapy. This approach aims to enhance the effectiveness of existing cancer therapies by improving the delivery of antibodies directly into tumor cells, facilitating better treatment outcomes in oncology.
ANTICARB attempts to exploit the advantages offered by a novel nanotechnology platform – carbon nanotubes – and apply them to a clinically established therapeutic modality – targeted antibody therapy – for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics.
ANTICARB combines two emerging technologies, antibody and nanotube technology, in a way that will allow safe development of antibody-nanotube conjugates and explore their swift translation into a clin…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Belgium, Bruxelles / Brussel
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Belgium, Sambreville
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Italy, Trieste
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
